Delivery Order SPE2DB22D1041-SPE2DB23FP5QX
- Not listed
- This federal contract award, valued at $13,947.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order for the supply of AMLOD-VALSA-HCTZ 5-160-25 MG 30S, a pharmaceutical product, with a period of performance through December 29, 2023. The contract was awarded on a full and open competitive basis without any set-aside designations. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $2,453.59, is a delivery order for the supply of pharmaceutical products, specifically AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a medication used to treat cardiovascular conditions. The contract is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora,...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $3,910.65, is for the delivery of AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a cardiovascular medication, to support military treatment facilities and veterans' healthcare programs. The award is not associated with a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract, valued at $3,695.56, is a delivery order for AMLODIPINE-ATORVAST 10-20 MG 30S, a cardiovascular medication. This award is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical, which serves as the primary vehicle...
- The federal contract award, valued at $59,382.11, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order to provide the pharmaceutical product Lotrel 10-20 mg capsules, a medication used for cardiovascular health. This award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA, valued at up to $999,999,999.00, which serves as the primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $2,812.78, is a delivery order for the supply of AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a pharmaceutical product. The contract has a completion date of September 21, 2023, and is a firm-fixed-price contract. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,453.31 firm fixed-price delivery order is for the supply of AMLOD-VALSA-HCTZ 10-320-25 MG 30S medication and has a performance period ending on May 16, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999.00 Indefinite Delivery Contract...
- This federal contract award is for the delivery of Amlodipine-Valsartan-Hydrochlorothiazide (AMLOD-VALSA-HCTZ) 10-320-25 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $1,758.42, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., on April 5, 2023. The award is a Delivery Order (DO) under an Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- This federal contract award, valued at $1,094.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract involves the delivery of Telmisartan-Amlodipine 40-10 30S, a pharmaceutical product, to support military treatment facilities and veteran healthcare programs. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,221.06 firm fixed-price delivery order provides for the purchase of Valsartan-HCTZ 320-25 mg tablets, a cardiovascular medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 held by Cencora, Inc. with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB23FP5QXDelivery Order
This federal contract award, valued at $5,007.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a pharmaceutical product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Cencora, Inc. also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These IDCs demonstrate the company's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 5/3/23 |